Drug intelligence / Profile preview

modified Wenjing decoction

Development stage
Preclinical
Lead developer
Kotaro Pharmaceuticals
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Modified Wenjing decoction is a variant of the traditional Chinese medicine (TCM) formula "Wenjing decoction" (Wen Jing Tang), which is historically used to warm the uterus and vessels, nourish blood, invigorate blood circulation, dispel cold and stasis, and regulate menstruation. The classic formula contains 12 herbs including Evodia fruit (Wu Zhu Yu), Angelica sinensis (Dang Gui), Ligusticum chuanxiong (Chuan Xiong), Cinnamon twig (Gui Zhi), Fresh ginger rhizome (Sheng Jiang), Pinellia ternata (Ban Xia), Licorice root (Gan Cao), Donkey-hide gelatin (E Jiao), Moutan cortex (Mu Dan Pi), Red peony root (Chi Shao or Bai Shao depending on source), Codonopsis root or Ginseng root, and Ophiopogon tuber. Modified versions may adjust these ingredients based on individual patient needs or specific clinical indications. The mechanism of action involves improving blood circulation, eliminating stasis, warming meridians to dispel cold, nourishing blood and yin, supporting digestive function via spleen tonification, and modulating immune/inflammatory pathways. Pharmacological studies suggest that active components in the formula may target inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukins like IL-10 and IL-1β; they also affect prostaglandin-endoperoxide synthase 2 activity among other targets[3]. Clinically it has been studied for primary dysmenorrhea due to cold coagulation/blood stasis[1], ovulatory disorder infertility[2], recurrent spontaneous abortion[3], menstrual irregularities[5][6][7], menopausal syndrome[5], among other gynecological conditions.

Other names
modified Wenjing decoctionmodified Wen Jing Tangmodified Warm the Menses Decoction
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)IL10 (Interleukin-10)IL1B (Interleukin-1 beta)TLR4 (Toll-like receptor 4)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on modified Wenjing decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on modified Wenjing decoction.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call